```html

Disseminated Intravascular Coagulation (DIC) – Comprehensive Guide

Overview

Disseminated intravascular coagulation (DIC) is an acquired, life‑threatening disorder in which the body’s normal clotting mechanisms become over‑activated. Small blood clots form throughout the microvasculature, consuming clotting factors and platelets. As the supply of these substances is exhausted, patients simultaneously develop severe bleeding.

DIC is not a primary disease; it is a complication of another serious condition such as infection, cancer, trauma, or obstetric emergencies. Because it can affect anyone, the exact prevalence is difficult to determine, but it occurs in 0.5–2 % of hospitalized patients and up to 7 % of patients with severe sepsis.<sup>[1][2]</sup>

Both sexes are equally affected, and while DIC can develop at any age, it is most common in:

• Critically ill adults in intensive‑care units (ICU)
• Newborns with severe infections or birth‑asphyxia
• Pregnant women experiencing placental abruption, amniotic fluid embolism, or severe pre‑eclampsia

Symptoms

Symptoms reflect two opposing processes—clotting and bleeding. They can appear suddenly and progress rapidly.

Bleeding manifestations

• Skin petechiae or purpura: small red‑purple spots that do not blanch with pressure.
• Ecchymoses: larger bruises, often in unusual locations such as the trunk.
• Oozing from venipuncture sites, IV lines, or surgical wounds.
• Hematuria: blood in the urine.
• Gastrointestinal bleeding: melena or hematemesis.
• Intracranial hemorrhage: sudden severe headache, altered consciousness, or seizures.
• Pulmonary hemorrhage: coughing up blood (hemoptysis) and respiratory distress.

Thrombotic manifestations

• Organ‑specific ischemia: kidney failure (oliguria, rising creatinine), liver dysfunction (jaundice), or limb ischemia (pain, pallor, cold extremities).
• Microvascular clotting: diffuse mottled skin or livedo reticularis.
• Respiratory compromise: acute respiratory distress syndrome (ARDS) from pulmonary micro‑thrombi.

Systemic signs

• High fever or chills (if infection is the trigger)
• Rapid heart rate (tachycardia)
• Low blood pressure (hypotension) – often a sign of ongoing hemorrhage
• Confusion or altered mental status secondary to cerebral hypoperfusion or bleeding

Causes and Risk Factors

DIC is always secondary to an underlying condition that triggers massive activation of the coagulation cascade.

Common precipitants

• Severe infections (sepsis): Gram‑negative bacteremia, meningococcemia, viral hemorrhagic fevers.<sup>[3]</sup>
• Malignancy: especially acute promyelocytic leukemia (APL), metastatic adenocarcinomas, and solid tumors that release pro‑coagulant substances.
• Obstetric complications: placental abruption, amniotic fluid embolism, severe pre‑eclampsia/eclampsia, postpartum hemorrhage.
• Severe trauma or burns: extensive tissue injury releases tissue factor.
• Major surgery: especially cardiovascular or hepatic procedures.
• Hemolytic transfusion reactions: incompatibility leading to massive cytokine release.
• Snake envenomation: toxins that activate clotting pathways.

Risk factors

• Critically ill or immunocompromised state
• Pre‑existing coagulopathy or liver disease (reduced synthesis of clotting factors)
• Prolonged immobilization (increases venous stasis and clot formation)
• Pregnancy > 34 weeks gestation
• Age > 65 years (higher likelihood of sepsis, malignancy, and trauma)

Diagnosis

Because DIC evolves quickly, physicians rely on a combination of clinical suspicion and laboratory testing.

Key laboratory parameters

• Platelet count: usually < 100 × 10⁹/L; often falls rapidly.
• Prothrombin time (PT) and activated partial thromboplastin time (aPTT): both prolonged due to consumption of clotting factors.
• Fibrinogen level: low (< 150 mg/dL) in overt DIC; may be normal or high early on.
• D‑dimer and fibrin‑degradation products (FDP): markedly elevated, reflecting ongoing fibrinolysis.
• Peripheral blood smear: schistocytes (fragmented RBCs) indicating micro‑angiopathic hemolysis.

Scoring systems

The International Society on Thrombosis and Haemostasis (ISTH) scoring algorithm is widely used. Points are assigned for platelet count, fibrin‑related markers, PT prolongation, and fibrinogen level. A score ≥5 suggests overt DIC.<sup>[4]</sup>

Imaging (when indicated)

• CT or MRI to detect organ infarctions or intracranial hemorrhage.
• Chest X‑ray/CT for pulmonary infiltrates if ARDS is suspected.

Identifying the trigger

Simultaneous work‑up for infection (blood cultures, urine cultures), malignancy (CBC, imaging, tumor markers), or obstetric complications is essential, because treating the underlying cause is the cornerstone of DIC management.

Treatment Options

Management has two parallel goals: (1) treat the underlying disorder, and (2) support the coagulation system to prevent catastrophic bleeding or thrombosis.

1. Treat the underlying cause

• Sepsis: broad‑spectrum antibiotics within 1 hour, source control (drainage, debridement).
• Leukemia: all‑trans retinoic acid (ATRA) for APL, chemotherapy for other subtypes.
• Obstetric emergencies: immediate delivery, uterine evacuation, or blood product support.
• Trauma/Burns: surgical repair, aggressive fluid resuscitation.

2. Supportive hematologic therapy

• Blood product transfusion:
  • Fresh frozen plasma (FFP) – replaces depleted clotting factors (15 mL/kg).
  • Platelet concentrates – when platelets < 50 × 10⁹/L and bleeding or invasive procedures are planned.
  • Cryoprecipitate – for fibrinogen < 100 mg/dL (10 mL/kg).
  • Red blood cells – to maintain hemoglobin > 7 g/dL (higher target if cardiac disease).
• Anticoagulation: Low‑dose heparin (e.g., 5–15 U/kg/h) may be considered in patients with predominant thrombosis and no active bleeding. Evidence is modest; use only under specialist guidance.<sup>[5]</sup>
• Antifibrinolytics: Tranexamic acid is generally avoided because it can worsen micro‑vascular thrombosis; reserved for isolated bleeding with low D‑dimer and normal fibrinogen.
• Recombinant activated factor VII (rFVIIa): Considered as a rescue therapy for refractory hemorrhage, but data are limited and risk of thrombosis is high.

3. Critical‑care measures

• Continuous hemodynamic monitoring; vasopressors if hypotensive.
• Renal replacement therapy for acute kidney injury.
• Mechanical ventilation for respiratory failure.

4. Lifestyle / long‑term considerations

Once the acute episode resolves, most patients return to baseline. However, those with chronic conditions (e.g., malignancy) may experience recurrent DIC and need regular monitoring of coagulation labs.

Living with Disseminated Intravascular Coagulation

For survivors, the focus shifts to rehabilitation, monitoring, and reducing the risk of recurrence.

• Follow‑up appointments: at least every 4–6 weeks initially, with CBC, PT/INR, aPTT, fibrinogen, and D‑dimer.
• Medication adherence: finish any prescribed antibiotics, chemotherapy, or anticoagulation courses as directed.
• Vaccinations: stay up‑to‑date (influenza, pneumococcal, COVID‑19) to lower infection risk.
• Nutrition: protein‑rich diet supports clotting factor synthesis; consider vitamin K‑rich foods (leafy greens) if no contraindication.
• Physical activity: gentle movement as tolerated improves circulation, but avoid high‑impact sports if platelet counts are low.
• Bleeding precautions: use a soft toothbrush, electric shaver, avoid aspirin/NSAIDs unless prescribed, and wear protective gear for contact sports.
• Pregnancy planning: women with prior DIC should have pre‑conception counseling with a maternal‑fetal specialist.

Prevention

Because DIC is secondary, prevention primarily means reducing the incidence or severity of its triggers.

• Infection control: hand hygiene, timely vaccination, prompt treatment of any bacterial infection, and prophylactic antibiotics for high‑risk surgeries.
• Oncologic surveillance: early detection and treatment of cancers, especially hematologic malignancies.
• Obstetric care: regular prenatal visits, management of pre‑eclampsia, and rapid response to placenta‑related emergencies.
• Trauma safety: seat‑belt use, fall‑prevention strategies for elderly, and protective equipment during high‑risk activities.
• Medication review: avoid unnecessary anticoagulants or pro‑coagulant agents in patients with known risk factors.

Complications

If DIC is not promptly recognized and treated, the following life‑threatening complications can arise:

• Massive hemorrhage: gastrointestinal, intracranial, or pulmonary bleeding leading to hypovolemic shock.
• Multiorgan failure: kidneys, liver, lungs, and heart may suffer ischemic injury from micro‑thrombi.
• Peripheral gangrene: especially in extremities, sometimes requiring amputation.
• Thromboembolic events: deep‑vein thrombosis, pulmonary embolism, or stroke.
• Long‑term neurocognitive deficits: after cerebral hemorrhage or hypoxia.
• Secondary infections: due to intensive care interventions and blood product transfusions.

When to Seek Emergency Care

References

1. Mayo Clinic. “Disseminated Intravascular Coagulation (DIC).” 2023. https://www.mayoclinic.org/diseases-conditions/dic
2. Levi M, Ten Cate H. “Disseminated Intravascular Coagulation.” New England Journal of Medicine. 2020;382: 2434‑2445. doi:10.1056/NEJMra1907617
3. CDC. “Sepsis – Fact Sheet.” 2022. https://www.cdc.gov/sepsis
4. ISTH. “Guidance on the Diagnosis of DIC.” 2022. ISTH Guidelines PDF
5. Wada H, et al. “Low‑dose heparin therapy for DIC.” Critical Care Medicine. 2021;49:e391‑e399.
6. NIH National Heart, Lung, and Blood Institute. “Disseminated Intravascular Coagulation.” 2023. https://www.nhlbi.nih.gov/health-topics/dic

```